chevron_leftBack
As of 13 June 2026, IGC Pharma, Inc. has a market cap of $30.61M USD, ranking #34111 globally and #4782 in the United States.
It ranks #3078 in the Healthcare sector, and #591 in the Biotechnology industry.
Key Stats
Market Cap
$30.61MUSD
Enterprise Value
$30.0MUSD
Revenue (TTM)
$1.11MUSD
EBITDA (TTM)
-$7.52MUSD
Net Income (TTM)
-$6.45MUSD
PS Ratio
28.0
PB Ratio
3.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Ram Mukunda
open_in_new
Employees
70
Founded
2005
Website
igcpharma.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.2% | -0.8% | 24% | 10% | -24% | 6.6% |
News
Loading...
IGC Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
IGC
IGC Pharma Inc
ISIN: US45408X3089
Shares Out.:
Shares Outstanding:
100.091M1
Shares Float:
77.265M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.3098 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About IGC Pharma, Inc.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
596K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
522K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
90K%
|
-
|
|
NYSE: IQV
|
$26.3B
86K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
82K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
59K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
156K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
146K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
138K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
138K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
92K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
84K%
|
-
|
chevron_leftBack